As we observe Stomach Cancer Awareness Month, it's important to educate ourselves on the risk factors, symptoms, and most common metastasis sites for this deadly disease. With early detection and ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

HOUSTON -- Two-thirds of patients with PI3K -mutant brain metastases responded to the maximum tolerated dose (MTD) of the ...

Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) for certain patients with advanced or metastatic breast cancer. Martha ...

Patients with microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) metastatic colorectal ... ethics committee at each site. All the patients provided written informed ...

Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

but subgroup analysis by a number of metastatic lesions suggested a potential overall survival benefit for radiotherapy in patients with <5 metastatic sites (HR: 0.68, 95% CI: 0.42-1.10): 3 STAMPEDE ...

You will be able to get a quick price and instant permission to reuse the content in many different ways. The humerus is a common site for metastatic bone disease and the common primaries include ...